Consolidation in Non-High-Risk Acute Promyelocytic Leukaemia (WBC ≤10 × 10&sup9;/L) Following Induction

Clinical Scenario

This protocol addresses patients with acute promyelocytic leukaemia (APL) classified as non-high-risk, defined by a white blood cell count of 10 × 10&sup9;/L or less at presentation.

Prior Induction Phase

These patients received induction with arsenic trioxide (ATO) and ATRA, aimed at achieving complete remission (CR or CRi) by day 28, or by day 60. This consolidation protocol is the defined next step following that induction phase and subsequent count recovery.

Consolidation Approach (Partial Overview)

After count recovery, a series of consolidation cycles is recommended, combining the two agents used in the induction phase. The full cycle count, scheduling, and sequencing are specified in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

Non-high-risk APL patients defined by a WBC count ≤10 × 10&sup9;/L should be treated with ATO and ATRA [I, A].

Consolidation treatment with ATO/ATRA should be started as soon as possible after count recovery.

Four 8-week consolidation cycles with ATO/ATRA are recommended, providing excellent cure rates to these patients.

View source ↗